Benzinga | Oct 22, 2020 08:41AM EDT

Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $110

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $100 to $110.